Press release
Type 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind Biosciences
Type 2 Diabetes - Pipeline Insight, 2026
DelveInsight's "Type 2 Diabetes - Pipeline Insight, 2026" report provides comprehensive insights about 75+ companies developing 80+ pipeline drugs in the Type 2 Diabetes pipeline landscape. It covers the Type 2 Diabetes pipeline drug profiles, including clinical and nonclinical stage products, along with therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights inactive pipeline products in this space.
Explore the latest breakthroughs in the Type 2 Diabetes treatment landscape. Learn more about the evolving Type 2 Diabetes pipeline today @ https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr
Key Takeaways from the Type 2 Diabetes Pipeline Report
*
On March 05, 2026, Eli Lilly and Company initiated a Phase 3 study to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control.
*
On March 03, 2026, AstraZeneca announced a Phase II study, a randomized, parallel group, double-blinded, placebo-controlled, multicenter trial, to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and Type 2 Diabetes on stable GLP-1 RA therapy.
*
DelveInsight's Type 2 Diabetes Pipeline Insight report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Type 2 Diabetes treatment.
*
The leading Type 2 Diabetes companies include Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others.
*
Promising Type 2 Diabetes therapies include Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others.
Download for updates and the latest revolution in Type 2 Diabetes care @ Type 2 Diabetes Clinical Trials Assessment [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Type 2 Diabetes Emerging Drugs Profile
*
XW014: Sciwind Biosciences XW014 is an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for the treatment of obesity and Type 2 Diabetes (T2D). XW014 functions as a GLP-1 receptor agonist, mimicking the action of the GLP-1 hormone released after meals. This hormone plays a key role in regulating glucose metabolism by stimulating insulin secretion, inhibiting glucagon release, and promoting satiety. As an oral small molecule, XW014 offers advantages over traditional peptide-based GLP-1 therapies, such as ease of administration and the potential for combination use with other oral medications. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
*
KN056: Suzhou Alphamab Co., Ltd. KN056 is a glucagon-like peptide-1 receptor (GLP-1R) modulator developed by Suzhou Alphamab Co., Ltd. KN056 targets the GLP-1 receptor - a key regulator of glucose metabolism that stimulates insulin secretion, inhibits glucagon release, and promotes satiety. By modulating the GLP-1 receptor, KN056 aims to improve glycemic control in patients with Type 2 Diabetes. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Type 2 Diabetes.
For more information on the Type 2 Diabetes Emerging Drugs Profile, download DelveInsight's comprehensive Type 2 Diabetes Pipeline Insight report [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Type 2 Diabetes Pipeline Report Provides
*
Detailed insights about companies developing therapies for Type 2 Diabetes, with aggregate therapies developed by each company.
*
Different therapeutic candidates, segmented into early-stage, mid-stage, and late-stage of development for Type 2 Diabetes treatment.
*
Type 2 Diabetes companies that are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Type 2 Diabetes drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company and company-academia), licensing agreements, and financing details for future advancement of the Type 2 Diabetes market.
Learn more about Type 2 Diabetes drug opportunities in our comprehensive Type 2 Diabetes pipeline report @ Type 2 Diabetes Unmet Needs [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Type 2 Diabetes Companies
There are 75+ key companies, such as Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others, developing therapies for Type 2 Diabetes, with Eli Lilly and Company having its Type 2 Diabetes drug candidate in the most advanced Phase III stage.
DelveInsight's Type 2 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Oral
*
Tropical
Type 2 Diabetes products have been categorized under various Molecule types such as:
*
Gene Therapy
*
Monoclonal antibody
*
Peptides
*
Polymer
*
Recombinant protein
*
Small molecule
Discover the latest advancements in Type 2 Diabetes treatment by visiting our website. Stay informed @ Type 2 Diabetes Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/type-2-diabetes-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Scope of the Type 2 Diabetes Pipeline Report
*
Coverage: Global
*
Type 2 Diabetes companies: Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, and others
*
Type 2 Diabetes Therapies: Empagliflozin, Subetta, AZD6234, AZD1656, Glipizide, iGlarLixi (insulin glargine/lixisenatide), GFT505 80mg, Pioglitazone, Metformin, Sulfonylurea, and others
*
Type 2 Diabetes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
*
Type 2 Diabetes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Table of Contents
*
Introduction
*
Executive Summary
*
Type 2 Diabetes: Overview
*
Pipeline Therapeutics
*
Therapeutic Assessment
*
Type 2 Diabetes - DelveInsight's Analytical Perspective
*
Late Stage Products (Phase III)
*
Mid Stage Products (Phase II)
*
Early Stage Products (Phase I)
*
Preclinical and Discovery Stage Products
*
Inactive Products
*
Type 2 Diabetes Key Companies
*
Type 2 Diabetes Key Products
*
Type 2 Diabetes Unmet Needs
*
Type 2 Diabetes Market Drivers and Barriers
*
Type 2 Diabetes Future Perspectives and Conclusion
*
Type 2 Diabetes Analyst Views
*
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=type-2-diabetes-clinical-trial-pipeline-expands-as-75-pharma-companies-progress-novel-therapies-toward-market-entry-finds-delveinsight-astrazeneca-eli-lilly-tonghua-dongbao-sciwind-biosciences]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Type 2 Diabetes Clinical Trial Pipeline Expands as 75+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AstraZeneca, Eli Lilly, Tonghua Dongbao, Sciwind Biosciences here
News-ID: 4471008 • Views: …
More Releases from ABNewswire
Hepatocellular Carcinoma Clinical Trial Pipeline Expands as 90+ Companies Drivin …
DelveInsight's "Hepatocellular Carcinoma Pipeline Insight 2026 report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Diabetic Macular Edema Clinical Trial Pipeline Shows Potential with Active Contr …
DelveInsight's "Diabetic Macular Edema Pipeline Insight 2026" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
Diffuse Large B-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 70+ Compan …
DelveInsight's, "Diffuse Large B-Cell Lymphoma Pipeline Insights 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Diffuse Large B-Cell…
HER2-Negative Breast Cancer Clinical Trial Pipeline Accelerates as 70+ Pharma Co …
DelveInsight's "HER2-Negative Breast Cancer Pipeline Insight 2026" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in HER2-Negative Breast Cancer pipeline landscape. It covers the HER2-Negative Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-Negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive…
More Releases for Type
Hydrotreating Catalysts Market, By Type (Load Type, Non-Load Type),size,Share,Tr …
The hydrotreating catalysts market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to reach at an estimated value of USD 1,700 million by 2028 and grow at a CAGR of 7.0% in the above-mentioned forecast period.
View Detailed Report: https://www.databridgemarketresearch.com/reports/global-hydrotreating-catalysts-market
Hydrotreating catalysts are the compounds which are primarily used in the procedure of refinery feedstock, under which sulfur, nitrogen and other contaminants…
Pressure Pumping Market 2028 By Type, Well Type, Resource Type and Geography
The Insight Partners delivers well-researched industry-wide information on the Pressure Pumping market. It provides information on the market's essential aspects such as top participants, factors driving Pressure Pumping market growth, precise estimation of the Pressure Pumping market size, upcoming trends, changes in consumer behavioral pattern, market's competitive landscape, key market vendors, and other market features to gain an in-depth analysis of the market. Additionally, the report is a compilation of…
Lawn Mowers Market Analysis By Type, End User, Product Type, Fuel Type, Engine P …
Lawn Mowers Market Analysis By Type(Manual, Electric, Petrol, Robotic), By End User(Residential, Commercial), By Product Type(Walk behind Movers, Ride on Movers, Stand on Movers), By Fuel Type(Gas Powered, Propane Powered), By Engine Power(Less than 15 hp, Between 15hp and 30 hp, More than 30 hp), By Blade Type(Cylinder, Standard, Mulching, Lifting), By Drive Type(AWD, FWD, RWD), By Application(Residential, Professional landscaping, Golf Course, Government), By Distribution Channel(Retail Store, Online Website) &…
Automotive Exhaust System Component Market Type, Fuel Type, Treatment Device, Ve …
Automotive Exhaust System Component Market
This report focuses on top manufacturers in global market, Involved the assessment of Sales, price, revenue and market share for each manufacturer, covering
Tenneco
Faurecia
Eberspacher
Boysen
Sango
HITER
Yutaka Giken
Calsonic Kansei
Magneti Marelli
Benteler
Sejong Industrial
Katcon
Futaba
Wanxiang
Bosal
Harbin Airui
Dinex
Catar
DSM
Get Sample PDF including full TOC, Tables and Figures @ https://www.ozonemarketreports.com/automotive-and-transportation/global-automotive-exhaust-system-components-market-professional-survey-report-2019/59563
On the basis of product, this report displays the Sales, revenue, price, market share and growth rate of each type, primarily split into
Exhaust Manifold
Exhaust Pipe
Catalytic Converter
Exhaust Temperature Sensor
Car Muffler
Exhaust…
Automotive Electric Vacuum Pump Market By Type Diaphragm Type, Swing Piston Type …
Automatic electric vacuum pump is a device that gets the drive from the camshaft in the engine. It can also be run by alternator shaft in some designs. It’s an added benefit to any engine, which has high performance. The primary function of an automatic electric vacuum pump is to drain out the air from brake booster tank hence creating the vacuum, which in turn can be used for application…
Marine Composites Market |By Type |Resin Type|Vessel Type|Fiber Type |Region Ana …
The report includes market segmentation by composites type (metal matrix composite, ceramic matrix composite, polymer matrix composite); polymer matrix composite by fiber type (glass fiber, carbon fiber, others); polymer matrix composite by resin type (polyester, vinyl ester, epoxy, thermoplastic, others); vessel type (power boats, sailboats, cruise ships, others); and region (North America, Europe, APAC, Latin America, MEA).
Download Latest Free PDF Sample Brochure of “Marine Composites Market” With Detailed TOC…
